In another study, the effects of combined therapy with PDT and a novel anti-angiogenic regimen using monoclonal antibodies against vascular endothelial growth factor receptors (VEGFR)-1 (MF1) and VEGFR-2 (DC101) were evaluated, demonstrating significant tumor growth inhibition and prolonged survival in animal models [54]. Here, FLT1 is linked to neoplasm.